Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
1. Zorevunersen shows durable seizure reduction and cognitive improvement over three years. 2. Phase 3 EMPEROR study for zorevunersen is now underway. 3. High retention rate (77%) in open-label extension studies. 4. Zorevunersen demonstrates potential as a disease-modifying treatment for Dravet syndrome. 5. Generally well tolerated, with manageable safety profile reported.